Jaguar8 commented on a stock · Aug 15, 2024 01:05

NEWS

RenovoRx Announces First Patient Enrolled at University of Nebraska Medical Center for the Ongoing Pivotal Phase III TIGeR-PaC Clinical Trial

RenovoRx (Nasdaq: RNXT) has announced the enrollment of the first patient at the University of Nebraska Medical Center (UNMC) for its ongoing Phase III TIGeR-PaC clinical trial. The study is evaluating RenovoGem™, a novel therapy for Locally Advanced Pancreatic Cancer (LAPC) using the TAMP™ (Trans-Arterial Micro-Perfusion) platform. This approach aims to deliver gemcitabine chemotherapy directly to the tumor site, potentially overcoming the challenge of drug penetration through the tumor's protective scar tissue.

The trial compares TAMP therapy to standard intravenous chemotherapy. UNMC, which joined the study in June 2024, is expected to help drive enrollment to completion by next year. The TIGeR-PaC study is currently enrolling unresectable LAPC patients across multiple US sites, reflecting RenovoRx's commitment to improving outcomes for patients with difficult-to-treat pancreatic cancer.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

3555 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8157

Followers

Following

93K

Visitors